Virpax Pharmaceuticals, Inc. received an extension from Nasdaq on July 29, 2024, to regain compliance with the minimum stockholders' equity requirement by September 30, 2024. The company had previously been notified of noncompliance due to its stockholders' equity falling below the required $2.5 million as of December 31, 2023. Additionally, during the 2024 Annual Meeting held on the same day, shareholders approved two amendments to the 2022 Equity Incentive Plan, increasing the number of shares available for grant and the annual 'evergreen provision' percentage. Eric Floyd and Gary Herman were elected as Class III directors, and EisnerAmper, LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2024.

Virpax Pharmaceuticals, Inc. received an extension from Nasdaq on July 29, 2024, to regain compliance with the minimum stockholders' equity requirement by September 30, 2024. The company had previously been notified of noncompliance due to its stockholders' equity falling below the required $2.5 million as of December 31, 2023. Additionally, during the 2024 Annual Meeting held on the same day, shareholders approved two amendments to the 2022 Equity Incentive Plan, increasing the number of shares available for grant and the annual 'evergreen provision' percentage. Eric Floyd and Gary Herman were elected as Class III directors, and EisnerAmper, LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2024.